A Review on Common Treatments for COVID-19 and Use of Tocilizumab (ACTEMRA) in Reducing Effects of the Disease

Abstract

Because of the increasing cases of COVID-19 and the lack of effective drugs for novel coronavirus pneumonia, there is an urgent need to find efficient targeted drugs. Based on the analysis of the disease spectrum in China, in addition to quarantine, a great number of patients require treatment immediately. In the absent of successful randomized controlled trials (RCTs), old anti-viral drugs and methods were used to treat patients that have been marketed for other purposes, such as anti-malarial drugs, biotherapy, interferon, and safety adjustment and as well as old Chinese medicine.

Studies on the effects of plasma on improved patients are promising. Several pharmaceutical companies have also begun testing for the vaccine all around the world.

Tocilizumab, the most effective way to inhibit CRS during cell therapy studies on chimeric antigen receptor T cells, and Karrizumab, as an inhibitor of immune system in NCP treatment, are highly important in treating the disease.

Under the brand name of Actemra, Tocilizumab was received approval from the US Food and Drug Administration on January 8, 2010. Tocilizumab Injection was used to treat adults with giant cells arthritis (GCA) and inflammation of the blood vessels (vasculitis). The use of this drug in the treatment of COVID-19 provides a significant remedial response because it is an anti-interleukin-6 receptor and recombinant humanized monoclonal antibody.